Zentalis Pharmaceuticals Inc
Suletud
4.05 -0.98
Ülevaade
Aktsiahinna muutus
24h
Min
4.01
Max
4.09
Sissetulek | -8.5M -35M |
|---|---|
Töötajad | 106 |
EBITDA | -11M -37M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +72.84% upside |
Järgmine tulemuste avaldamine | 19. mai 2026 |
|---|
Turukapital | 131M 295M |
|---|---|
Eelmine avamishind | 5.03 |
Eelmine sulgemishind | 4.05 |
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Zentalis Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Zentalis Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
72.84% tõus
12 kuu keskmine prognoos
Keskmine 7 USD 72.84%
Kõrge 10 USD
Madal 4 USD
Põhineb 7 Wall Streeti analüütiku instrumendi Zentalis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
